<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01524133</url>
  </required_header>
  <id_info>
    <org_study_id>PROGrESS</org_study_id>
    <nct_id>NCT01524133</nct_id>
  </id_info>
  <brief_title>PROlonGed ExpoSure Sertraline</brief_title>
  <acronym>PROGrESS</acronym>
  <official_title>Randomized Trial of Sertraline, Prolonged Exposure, and Their Combination for Post-traumatic Stress Disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Ann Arbor Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Ann Arbor Healthcare System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current research study aims to compare the effectiveness of two proven treatments for
      posttraumatic stress disorder (PTSD): Prolonged Exposure (PE), sertraline, and their
      combination. In addition, the investigators are examining predictors of response to these two
      treatments and how PTSD symptoms, thoughts, and biological factors may be changed by such
      treatments. Biological mechanisms of change are also examined including emotion processing
      and regulation in fMRI, HPA axis function, and genetics and genomics. In addition, the
      investigators will examine acceptability of each treatment and reasons for ending treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Posttraumatic Stress Disorder (PTSD) Symptoms as Measured by the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Total Score; Range 0-136 with increasing PTSD severity as scores increase</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire-15</measure>
    <time_frame>24 weeks</time_frame>
    <description>PHQ-15; measures somatization and ranges from 0 to 30 and 0-9 is considered minimal/low, 10-14 is moderate, and 15-30 is severe</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">223</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline + enhanced medication management (SERT/EMM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>24 weeks of sertraline + enhanced medication management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prolonged Exposure + sertraline (PE/SERT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prolonged Exposure + placebo (PE/PLB)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.</description>
    <arm_group_label>Sertraline + enhanced medication management (SERT/EMM)</arm_group_label>
    <arm_group_label>Prolonged Exposure + sertraline (PE/SERT)</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Prolonged Exposure Therapy</intervention_name>
    <description>up to 13 sessions of prolonged exposure</description>
    <arm_group_label>Prolonged Exposure + sertraline (PE/SERT)</arm_group_label>
    <arm_group_label>Prolonged Exposure + placebo (PE/PLB)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is an Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn
             (OEF/OIF/OND) combat veteran with chronic posttraumatic stress disorder (PTSD) or
             significant PTSD symptoms (Clinician Administered Posttraumatic Stress Disorder Scale
             [CAPS] &gt;= 50) of at least 3 months duration

        Exclusion Criteria:

          -  Current, imminent risk of suicide (as indicated on C-SSRS)

          -  Active psychosis

          -  Alcohol or substance dependence in the past 8 weeks

          -  Unable to attend regular appointments

          -  Prior intolerance or failure of adequate trial of prolonged exposure (PE) or
             sertraline (SERT) (defined as at least 2 months of SERT at least 100mg/day)

          -  Medical illness likely to result in hospitalization or for which treatments are
             contraindicated (based on lab results, medical history and physical exam)

          -  Serious cognitive impairment (as evidenced by cognitive impairment felt likely to
             interfere with the ability to participate meaningfully in the study)

          -  Concurrent antidepressants or antipsychotics

          -  Pregnant females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila Rauch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Ann Arbor Healthcare System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA San Diego Healthcare System</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ralph H. Johnson VA Medical Center/Savannah Primary Care Clinic</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Ann Arbor Healthcare System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>January 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2012</study_first_posted>
  <results_first_submitted>December 6, 2017</results_first_submitted>
  <results_first_submitted_qc>January 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2018</results_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atlanta VA Medical Center</investigator_affiliation>
    <investigator_full_name>Sheila Rauch</investigator_full_name>
    <investigator_title>Clinical Director of Wounded Warrior Project and Associate Professor at Emory University, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>combat-related PTSD</keyword>
  <keyword>Posttraumatic stress disorder</keyword>
  <keyword>prolonged exposure therapy</keyword>
  <keyword>sertraline</keyword>
  <keyword>military</keyword>
  <keyword>veterans</keyword>
  <keyword>VA hospital</keyword>
  <keyword>mental illness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Patients were informed of assignment at first treatment visit. Only those randomized patients who started treatment are included below (16 patients never started treatment. They did not know condition assignment.).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sertraline + Enhanced Medication Management (SERT/EMM)</title>
          <description>24 weeks of sertraline + enhanced medication management
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.</description>
        </group>
        <group group_id="P2">
          <title>Prolonged Exposure + Sertraline (PE/SERT)</title>
          <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
        </group>
        <group group_id="P3">
          <title>Prolonged Exposure + Placebo (PE/PLB)</title>
          <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52">Completed Both Assigned treatment</participants>
                <participants group_id="P2" count="37">Completed Both Assigned Treatments</participants>
                <participants group_id="P3" count="31">Completed both assigned treatments</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Overall Study 52 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sertraline + Enhanced Medication Management (SERT/EMM)</title>
          <description>24 weeks of sertraline + enhanced medication management
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.</description>
        </group>
        <group group_id="B2">
          <title>Prolonged Exposure + Sertraline (PE/SERT)</title>
          <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
        </group>
        <group group_id="B3">
          <title>Prolonged Exposure + Placebo (PE/PLB)</title>
          <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="67"/>
            <count group_id="B4" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.7" spread="8.2"/>
                    <measurement group_id="B2" value="35.1" spread="8.5"/>
                    <measurement group_id="B3" value="34.7" spread="8.3"/>
                    <measurement group_id="B4" value="34.5" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Posttraumatic Stress Disorder (PTSD) Symptoms as Measured by the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</title>
        <description>Total Score; Range 0-136 with increasing PTSD severity as scores increase</description>
        <time_frame>24 weeks</time_frame>
        <population>All randomized patients who received treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline + Enhanced Medication Management (SERT/EMM)</title>
            <description>24 weeks of sertraline + enhanced medication management
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.</description>
          </group>
          <group group_id="O2">
            <title>Prolonged Exposure + Sertraline (PE/SERT)</title>
            <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
          </group>
          <group group_id="O3">
            <title>Prolonged Exposure + Placebo (PE/PLB)</title>
            <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Posttraumatic Stress Disorder (PTSD) Symptoms as Measured by the Clinician Administered Posttraumatic Stress Disorder Scale (CAPS)</title>
          <description>Total Score; Range 0-136 with increasing PTSD severity as scores increase</description>
          <population>All randomized patients who received treatment</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7" spread="25.7"/>
                    <measurement group_id="O2" value="43.3" spread="27.2"/>
                    <measurement group_id="O3" value="51.5" spread="25.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Health Questionnaire-15</title>
        <description>PHQ-15; measures somatization and ranges from 0 to 30 and 0-9 is considered minimal/low, 10-14 is moderate, and 15-30 is severe</description>
        <time_frame>24 weeks</time_frame>
        <population>All Randomized patients who received treatment and had the measure</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline + Enhanced Medication Management (SERT/EMM)</title>
            <description>24 weeks of sertraline + enhanced medication management
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.</description>
          </group>
          <group group_id="O2">
            <title>Prolonged Exposure + Sertraline (PE/SERT)</title>
            <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
          </group>
          <group group_id="O3">
            <title>Prolonged Exposure + Placebo (PE/PLB)</title>
            <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Health Questionnaire-15</title>
          <description>PHQ-15; measures somatization and ranges from 0 to 30 and 0-9 is considered minimal/low, 10-14 is moderate, and 15-30 is severe</description>
          <population>All Randomized patients who received treatment and had the measure</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="5.7"/>
                    <measurement group_id="O2" value="9.8" spread="5.7"/>
                    <measurement group_id="O3" value="10.5" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>52 weeks (24 Weeks of Treatment Phase and 28 weeks of follow-up)</time_frame>
      <desc>Individual descriptions were summarized to organ class</desc>
      <group_list>
        <group group_id="E1">
          <title>Sertraline + Enhanced Medication Management (SERT/EMM)</title>
          <description>24 weeks of sertraline + enhanced medication management
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.</description>
        </group>
        <group group_id="E2">
          <title>Prolonged Exposure + Sertraline (PE/SERT)</title>
          <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of sertraline
Sertraline: Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
        </group>
        <group group_id="E3">
          <title>Prolonged Exposure + Placebo (PE/PLB)</title>
          <description>Up to 13 sessions of prolonged exposure therapy + 24 weeks of placebo
Prolonged Exposure Therapy: up to 13 sessions of prolonged exposure</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Increased Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Increased Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematological</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="94" subjects_affected="49" subjects_at_risk="71"/>
                <counts group_id="E2" events="68" subjects_affected="34" subjects_at_risk="69"/>
                <counts group_id="E3" events="39" subjects_affected="20" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muskuloskeletal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="69"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="38" subjects_affected="27" subjects_at_risk="71"/>
                <counts group_id="E2" events="29" subjects_affected="22" subjects_at_risk="69"/>
                <counts group_id="E3" events="17" subjects_affected="14" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychological</sub_title>
                <counts group_id="E1" events="40" subjects_affected="25" subjects_at_risk="71"/>
                <counts group_id="E2" events="36" subjects_affected="24" subjects_at_risk="69"/>
                <counts group_id="E3" events="25" subjects_affected="15" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Genitourinary</sub_title>
                <counts group_id="E1" events="36" subjects_affected="25" subjects_at_risk="71"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="69"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="71"/>
                <counts group_id="E2" events="18" subjects_affected="10" subjects_at_risk="69"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="71"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sheila Rauch</name_or_title>
      <organization>Atlanta VAMC</organization>
      <phone>404-321-6111 ext 3122</phone>
      <email>sheila.rauch@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

